NeuBase Therapeutics, Inc. NASDAQ:NBSE NeuBase Therapeutics Inc. is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions.

Location: 700 Technology Dr, Pennsylvania, 15219-3124, US | Website: www.neubasetherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing